Abstracts Archive - Page 2132 of 2607 - ACR Meeting Abstracts

Abstract Number: 1537 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics of RA Patients Newly Prescribed Tofacitinib Citrate (tofacitinib) in the United States after Food and Drug Administration Approval: Results from the Corrona US Rheumatoid Arthritis Registry
Arthur Kavanaugh¹, George W. Reed^2,3, Katherine C. Saunders², Andrew S. Koenig⁴, Jamie Geier⁵, Joel M. Kremer⁶, Jeffrey D. Greenberg^2,7 and Clifton O. Bingham III⁸, ¹University of California San Diego, La Jolla, CA, ²Corrona, LLC., Southborough, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Pfizer, Inc., Collegeville, PA, ⁵Pfizer, Inc., New York, NY, ⁶Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁷Rheumatology, New York University School of Medicine, New York, NY, ⁸Johns Hopkins University, Baltimore, MD
Background/Purpose: To provide initial characterization of the patients prescribed tofacitinib during the early period after United States (US) Food and Drug Administration (FDA) approval (11/6/2012).…
Abstract Number: 1536 • 2014 ACR/ARHP Annual Meeting
Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Isabelle Fortin³, Boulos Haraoui¹, Jean Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard⁴, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The order of use of biologic agents is still a question for debate. Phase III trial data in MTX-IR patients show comparable efficacy results…
Abstract Number: 1535 • 2014 ACR/ARHP Annual Meeting
Use of Rituximab Compared to Anti-Tnf Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: A Report from the rhumadata® Clinical Database and registry
Denis Choquette¹, Jean-Pierre Raynauld¹, Jean Pierre Pelletier¹, Boulos Haraoui¹, Louis Bessette², Edith Villeneuve¹, Marie-Anaïs Rémillard³, Isabelle Fortin⁴, Diane Sauvageau¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁴Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada
Background/Purpose: The order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR…
Abstract Number: 1534 • 2014 ACR/ARHP Annual Meeting
Disease Severity and Treatment of Rheumatoid Arthritis: A Comparative Study Between Sudan and Sweden
Amir Elshafie¹, Abdalla D Elkhalifa², Thomas Weitoft³, Musa Nur⁴, Elnour Elagib⁵, Mawahib Aledrissy⁶, Sahwa Elbagir⁷ and Johan Rönnelid⁸, ¹Immunology, Genetics and Pathology, MD, MDpath, PhD, Uppsala, Sweden, ²Rheumatology unit, MD, Gävle, Sweden, ³Rheumatology unit, MD, PhD, Gävle, Sweden, ⁴Alribat University Hospital, MD, FRCP, Khartoum, Sudan, ⁵Rheumatology unit, Alribat University Hospital, MD, FRCP, Khartoum, Sudan, ⁶Rheumatology unit, Alribat University Hospital, MD, MD internal Medicine, Khartoum, Sudan, ⁷Immunology, Genetics and Pathology, M, PhD student, Uppsala, Sweden, ⁸Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
Background/Purpose: To perform a comparative study concerning clinical characteristics and treatment between Sudanese and Swedish RA outpatients. Methods: A 286 Sudanese and 542 Swedish RA…
Abstract Number: 1516 • 2014 ACR/ARHP Annual Meeting
TNF-Alpha Inhibitors Normalizes Melanocortin Receptor Subtype 2, 3 and 4 Expression in CD8+, CD14+ and CD19+ Leukocyte Subsets in Rheumatoid Arthritis
Marlene Andersen¹, Michael Kruse Meyer², Ivan Nagaev³, Olga Nagaeva³, Jarl E.S. Wikberg⁴, Lucia Mincheva-Nilsson³ and Grethe N. Andersen², ¹Department of Rheumatology, Aalborg University, Hjørring, Denmark, ²Clinic of Rheumatology, Hospital of Vendsyssel/Aalborg University, Hjørring, Denmark, ³Department of Clinical Immunology, University of Umeå, Umeå, Sweden, ⁴Department of Pharmaceutical Biosciences, Department of Pharmaceutical Pharmacology, Uppsala, Sweden
Background/Purpose: We examined Adalimumab´s effects on melanocortin receptor subtype (MC)1-5 gene expression in important leukocyte subsets in rheumatoid arthritis (RA). The melanocortin system is a…
Abstract Number: 1515 • 2014 ACR/ARHP Annual Meeting
The Impact on Anti-Citrullinated Protein Antibody Isotypes and Epitope Fine Specificity in Patients with Early RA Treated with Abatacept and Methotrexate
T W J Huizinga¹, S E Connolly², Daniel E. Furst³, Vivian P. Bykerk⁴, Gerd Burmester⁵, B G Combe⁶, C S Karyekar², D Wong², L Trouw¹, R E M Toes⁷ and P Emery⁸, ¹Leiden University Medical Center, Leiden, Netherlands, ²Bristol-Myers Squibb, Princeton, NJ, ³University of California at Los Angeles, Los Angeles, CA, ⁴Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁵Charité – University Medicine Berlin, Berlin, Germany, ⁶Montpellier University Hospital, Montpellier, France, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a marker of RA and may contribute to disease progression.1,2 ACPA analysis in patients offers the opportunity to estimate…
Abstract Number: 1514 • 2014 ACR/ARHP Annual Meeting
An Analysis of in-Vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically-Meaningful Concentrations
M.E. Dowty, T.S. Lin, L. Wang, J. Jussif, B. Juba, L. Li, E. Moy and J.-B. Telliez, Pfizer Worldwide R&D, Cambridge, MA
Background/Purpose: A number of Janus kinase (JAK) inhibitors are being actively investigated for treatment of rheumatoid arthritis (RA), including tofacitinib, baricitinib, filgotinib (GLPG0634), and decernotinib…
Abstract Number: 1513 • 2014 ACR/ARHP Annual Meeting
Selection of Vagus Nerve Stimulation Parameters for a First-in-Human Study in Rheumatoid Arthritis: A Unique Translational Medicine Challenge
Frieda A. Koopman¹, Yaakov Levine², Mike Faltys², Ralph Zitnik² and Paul P. Tak³, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²SetPoint Medical Corporation, Valencia, CA, ³Departments of Experimental Immunology and Internal Medicine, GlaxoSmithKline U.K. and Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Cholinergic anti-inflammatory pathway (CAP) activation by electrical vagus nerve stimulation (VNS) is being studied in rheumatoid arthritis (RA) trials (NCT01552941). CAP signaling proceeds sequentially…
Abstract Number: 1512 • 2014 ACR/ARHP Annual Meeting
Therapeutic Efficacy of a Novel Oral Small Molecule Macrophage Migration Inhibitory Factor [MIF] Inhibitor: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Anderson Gaweco^1,2, Samantha Palmer², Rambon Shamilov², Caroline Stremnitzer², Michael Fisher², Gregg Crichlow², William Windsor², Ellen M. Ginzler³ and Jefferson Tilley², ¹SUNY-Downstate Medical Center, Brooklyn, NY, ²Innovimmune Biotherapeutics, Brooklyn, NY, ³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: Macrophage migration inhibitory factor [MIF] is a cytokine secreted by activated T cells and macrophages that plays an important role in RA and autoimmune…
Abstract Number: 1511 • 2014 ACR/ARHP Annual Meeting
COVA322: A Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Wibke Lembke, Bernd Schlereth, Julian Bertschinger, Dragan Grabulovski and Mathias Locher, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologic therapeutics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there is still…
Abstract Number: 1510 • 2014 ACR/ARHP Annual Meeting
Blockade of TLR5 Ligation Is a Novel Strategy for RA Therapy
Seung-jae Kim¹, Zhenlong Chen¹, Abdul Essani², Michael Volin³, Suncica Volkov¹, William Swedler⁴, Shiva Arami², Nadera J. Sweiss⁵ and Shiva Shahrara¹, ¹Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, ²University of Illinois at Chicago, Chicago, IL, ³Microbiology & Immunology, Midwestern University, Downers Grove, IL, ⁴Section of Rheumatology, University of Illinois at Chicago, Chicago, IL, ⁵internal medicine section of rheumatology, University of Illinois at Chicago, Chicago, IL
Background/Purpose: TLR5 expression is highly elevated in RA and CIA lining and sublining macrophages and endothelial cells compared to non-arthritic controls. Additionally, expression of TLR5…
Abstract Number: 1509 • 2014 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Three-Arm, Parallel Group, Single-Dose Study to Compare the Pharmacokinetics, Safety, and Tolerability of Three Formulations of Infliximab (CT-P13, EU-sourced Infliximab and US-sourced Infliximab) in Healthy Volunteers
Dae-Hyun Yoo¹, Won Park², Seung-Cheol Shim³, Chang-Hee Suh⁴, Jihye Yun⁵ and Tina Pyo⁵, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Chungnam National University Hospital, Daejeon, South Korea, ⁴Allergy-Rheumatology, Ajou University Hospital, Suwon, South Korea, ⁵CELLTRION, Inc, Incheon, South Korea
Background/Purpose CT-P13 has been approved as the first biosimilar to innovator infliximab sourced from European Union (EU‑INX) in Sep 2013. Even if it has been…
Abstract Number: 1508 • 2014 ACR/ARHP Annual Meeting
Impact of Anti-Drug Antibody on Efficacy and Safety over Week 24 in Both CT-P10 and Innovator Rituximab Treatment Groups
Dae-Hyun Yoo¹, Won Park², Slawomir Jeka³, Fidencio Cons Molina⁴, Pawel Hrycaj⁵, Piotr Wiland⁶, Wolfgang Spieler⁷, Eun Young Lee⁸, Francisco G. Medina-Rodriguez⁹, Pavel Shesternya¹⁰, Sebastiao Radominski¹¹, Dong Hyuk Sheen¹², Mie Jin Lim¹³, Jung-Yoon Choe¹⁴, Leysan Myasoutova¹⁵, Taek Kwon¹⁶, Sang Joon Lee¹⁶, Seung-Cheol Shim¹⁷ and Chang-Hee Suh¹⁸, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁴Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁵Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ⁶Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁷Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁸Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁹Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, ¹⁰Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹¹CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, ¹²Rheumatology, Eulji University Hospital, DaeJeon, South Korea, ¹³Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ¹⁴Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, ¹⁵City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, ¹⁶CELLTRION, Inc., Incheon, South Korea, ¹⁷Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ¹⁸Allergy-Rheumatology, Ajou University Hospital, Suwon, South Korea
Background/Purpose CT-P10 is a biosimilar candidate for rituximab. Pharmacokinetic equivalence and similarity of clinical efficacy, safety and immunogenicity had been demonstrated between CT-P10 and Innovator…
Abstract Number: 1507 • 2014 ACR/ARHP Annual Meeting
Patient Perspectives on the Introduction of Subsequent Entry Biologics in Canada
Suneet Sekhon¹, Raman Rai¹, Debbie McClory², Carolyn Whiskin², Melissa Deamude³, Cynthia Mech⁴, Lauri Vanstone², Alpesh Shah⁵, Arthur N. Lau⁶ and William Bensen⁷, ¹Rheumatology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ³Dr William G Bensen Medicine Professional Corp, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁴Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁵Epidemiology and Biostatistics, University of Western Ontario, MSc in Clinical Epidemiology, University of Western Ontario, London, ON, Canada, ⁶Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Division of Rheumatology, McMaster University, Hamilton, ON, Canada
Background/Purpose: Biologic medications have revolutionized the treatment of inflammatory arthritis. Subsequent entry biologics (SEBs) or biosimilars are medications that are similar but not identical to…
Abstract Number: 1506 • 2014 ACR/ARHP Annual Meeting
Incidence of Adverse Events in Patients Treated with Intended Copies of Biologic Therapeutic Agents in Colombia and Mexico
Leonor A. Barile-Fabris¹, Fedra Irazoque-Palazuelos², Ramiro Hernández Vásquez³, Sandra Carrillo Vazquez⁴ and R. Gúzman⁵, ¹Rheumatology Department, Hospital Especialidades CMN, Mexico City, Mexico, ²Centro Médico Nacional "20 de Noviembre" ISSSTE, Mexico City, Mexico, ³Rheumatology, Hospital de Especialidades “Dr. Bernardo Sepúlveda Gutiérrez”, Mexico, Mexico, ⁴Rheumatology, Hospital Angeles Lindavista, Mexico DF, Mexico, ⁵IDEARG, SaludCoop, Bogotá, Colombia
Background/Purpose: A biosimilar is a copy of an approved biologic therapeutic agent that has undergone rigorous evaluation to ensure that it is similar to the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].